Sage Therapeutics Announces FDA Acceptance of NDA Filing and Grant of Priority Review for Brexanolone IV in the Treatment of Postpartum Depression

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 30, 2018-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the U.S....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news